These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32426918)

  • 21. Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy.
    Citraro R; Aiello R; Franco V; De Sarro G; Russo E
    Expert Opin Ther Targets; 2014 Mar; 18(3):319-34. PubMed ID: 24387310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
    Chonan M; Saito R; Kanamori M; Osawa SI; Watanabe M; Suzuki H; Nakasato N; Tominaga T
    Neurol Med Chir (Tokyo); 2020 Jan; 60(1):37-44. PubMed ID: 31748440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of spontaneous and evoked epileptiform activity in three in vitro epilepsy models.
    Gulyás-Kovács A; Dóczi J; Tarnawa I; Détári L; Banczerowski-Pelyhe I; Világi I
    Brain Res; 2002 Aug; 945(2):174-80. PubMed ID: 12126879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy.
    El Desoky ES
    Fundam Clin Pharmacol; 2014 Oct; 28(5):473-80. PubMed ID: 24750493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AMPA receptor activation reduces epileptiform activity in the rat neocortex.
    Addae JI; Ali N; Youssef FF; Stone TW
    Brain Res; 2007 Jul; 1158():151-7. PubMed ID: 17543292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of calcium-permeable and calcium-impermeable AMPA receptors by perampanel in rat brain neurons.
    Barygin OI
    Neurosci Lett; 2016 Oct; 633():146-151. PubMed ID: 27663136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Src/CK2/PTEN-Mediated GluN2B and CREB Dephosphorylations Regulate the Responsiveness to AMPA Receptor Antagonists in Chronic Epilepsy Rats.
    Kim JE; Lee DS; Park H; Kang TC
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro.
    Klapstein GJ; Colmers WF
    J Neurophysiol; 1997 Sep; 78(3):1651-61. PubMed ID: 9310450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deregulation of Astroglial TASK-1 K
    Lee DS; Kim TH; Park H; Kang TC
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982567
    [No Abstract]   [Full Text] [Related]  

  • 30. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity.
    Bigge CF; Malone TC; Boxer PA; Nelson CB; Ortwine DF; Schelkun RM; Retz DM; Lescosky LJ; Borosky SA; Vartanian MG
    J Med Chem; 1995 Sep; 38(19):3720-40. PubMed ID: 7562904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy.
    Faught E
    Expert Opin Investig Drugs; 2014 Jan; 23(1):107-13. PubMed ID: 24147649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AMPA receptors in epilepsy and as targets for antiepileptic drugs.
    Rogawski MA; Donevan SD
    Adv Neurol; 1999; 79():947-63. PubMed ID: 10514878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus.
    Willems LM; Bauer S; Rosenow F; Strzelczyk A
    Expert Opin Pharmacother; 2019 Oct; 20(14):1755-1765. PubMed ID: 31264486
    [No Abstract]   [Full Text] [Related]  

  • 34. Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre.
    Morano A; Fattouch J; Albini M; Casciato S; Fanella M; Basili LM; Viganò A; Manfredi M; Giallonardo AT; Di Bonaventura C
    J Neurol Sci; 2018 Jul; 390():67-74. PubMed ID: 29801910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery.
    Lattanzi S; Striano P
    Expert Opin Drug Discov; 2019 Mar; 14(3):195-197. PubMed ID: 30633590
    [No Abstract]   [Full Text] [Related]  

  • 36. Weak blockade of AMPA receptor-mediated depolarisations in the rat cortical wedge by phenytoin but not lamotrigine or carbamazepine.
    Phillips I; Martin KF; Thompson KS; Heal DJ
    Eur J Pharmacol; 1997 Oct; 337(2-3):189-95. PubMed ID: 9430413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of AMPA receptor blockade on resting magnetoencephalography recordings.
    Routley BC; Singh KD; Hamandi K; Muthukumaraswamy SD
    J Psychopharmacol; 2017 Dec; 31(12):1527-1536. PubMed ID: 29084475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of perampanel in patients with intellectual disability and epilepsy.
    Snoeijen-Schouwenaars FM; van Ool JS; Tan IY; Schelhaas HJ; Majoie MH
    Epilepsy Behav; 2017 Jan; 66():64-67. PubMed ID: 28038388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences.
    Biró A; Stephani U; Tarallo T; Bast T; Schlachter K; Fleger M; Kurlemann G; Fiedler B; Leiz S; Nikanorova M; Wolff M; Müller A; Selch C; Staudt M; Kluger G
    Neuropediatrics; 2015 Apr; 46(2):110-6. PubMed ID: 25730374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perampanel as add-on treatment in refractory focal epilepsy. The Dianalund experience.
    Juhl S; Rubboli G
    Acta Neurol Scand; 2016 Nov; 134(5):374-377. PubMed ID: 26763771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.